9 results on '"Waseda K"'
Search Results
2. Diagnostic Performance of High-Resolution Intravascular Ultrasound for the Detection of Plaque Rupture in Patients With Acute Coronary Syndrome.
- Author
-
Ohashi H, Ando H, Takashima H, Waseda K, Shimoda M, Fujimoto M, Sawada H, Suzuki A, Sakurai S, Nakano Y, and Amano T
- Subjects
- Acute Coronary Syndrome therapy, Aged, Coronary Artery Disease therapy, Female, Humans, Male, Middle Aged, Percutaneous Coronary Intervention, Predictive Value of Tests, Prospective Studies, Reproducibility of Results, Rupture, Spontaneous, Tomography, Optical Coherence, Acute Coronary Syndrome diagnostic imaging, Coronary Artery Disease diagnostic imaging, Plaque, Atherosclerotic, Ultrasonography, Interventional
- Abstract
Background: The new 60-MHz high-resolution intravascular ultrasound (HR-IVUS) is the next-generation IVUS technology, providing higher image resolution than conventional IVUS. It gives clear images of plaque morphology and can discriminate the underlying mechanism of acute coronary syndrome (ACS). Our study aimed to evaluate the diagnostic performance of 60-MHz HR-IVUS in the detection of plaque rupture in patients with ACS., Methods and results: Patients with ACS who underwent percutaneous coronary intervention for de novo native coronary artery lesions were enrolled. Both HR-IVUS and optical coherence tomography (OCT) were performed for the culprit lesions prior to interventions other than aspiration thrombectomy. Keeping plaque rupture detected by OCT as the gold standard, the diagnostic performance of HR-IVUS was evaluated. Overall, 70 patients underwent both HR-IVUS and OCT examinations. Of these, imaging assessments by HR-IVUS were available for all 70 patients (100%), and those by OCT were available for 54 patients (77.1%). Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of HR-IVUS for identifying a plaque rupture were 84.8%, 57.1%, 75.7%, 70.6%, and 74.1%, respectively., Conclusions: HR-IVUS had high sensitivity, but modest specificity for identifying OCT-derived plaque rupture. Compared with results from previous conventional IVUS studies, HR-IVUS might have increased ability to detect OCT-derived plaque rupture, but there is still substantial scope for improvement, especially in the specificity. more...
- Published
- 2019
- Full Text
- View/download PDF
Catalog
3. Early-Phase Vascular Healing of Bioabsorbable vs. Durable Polymer-Coated Everolimus-Eluting Stents in Patients With ST-Elevation Myocardial Infarction - 2-Week and 4-Month Analyses With Optical Coherence Tomography.
- Author
-
Shimoda M, Ando H, Naito K, Suzuki A, Sakurai S, Nakano Y, Kurita A, Waseda K, Takashima H, Murotani K, Uetani T, and Amano T
- Subjects
- Aged, Coronary Vessels surgery, Drug-Eluting Stents adverse effects, Everolimus administration & dosage, Everolimus therapeutic use, Female, Humans, Male, Middle Aged, Neointima diagnostic imaging, ST Elevation Myocardial Infarction therapy, Thrombosis prevention & control, Tomography, Optical Coherence, Wound Healing drug effects, Drug-Eluting Stents standards, Thrombosis etiology
- Abstract
Background: Despite the revolution of coronary stents, there remain concerns about the risk of stent thrombosis, especially in patients with ST-elevation myocardial infarction (STEMI). The present study compared early vascular healing as a contributing factor to reducing stent thrombosis between Xience everolimus-eluting stents (X-EES) and Synergy everolimus-eluting stents (S-EES) in patients with STEMI., Methods and results: The present study included 47 patients with STEMI requiring primary percutaneous coronary intervention with X-EES (n=25) or S-EES (n=22). Optical coherence tomography (OCT) assessments of the stented lesions were performed 2 weeks and 4 months after stent implantation. Neointimal strut coverage, malapposition and the frequency of thrombus formation were evaluated. In the 2-week OCT analysis, the proportion of covered struts in S-EES (42.4±15.4%) was significantly higher than in X-EES (26.3±10.1%, P<0.001). In the 4-month OCT analysis, the proportion of covered struts in S-EES (72.2±17.9%) was still significantly higher than in X-EES (62.0±14.9%, P=0.04)., Conclusions: Compared with X-EES, S-EES showed a higher proportion of covered struts in the early phase after stent implantation for STEMI patients. more...
- Published
- 2018
- Full Text
- View/download PDF
4. Comparison of vascular response to zotarolimus-eluting stent vs paclitaxel-eluting stent implantation: pooled IVUS results from the ZoMaxx I and II trials.
- Author
-
Waseda K, Hasegawa T, Ako J, Honda Y, Grube E, Whitbourn R, Ormiston J, O'Shaughnessy CD, Henry TD, Overlie P, Schwartz LB, Sudhir K, Chevalier B, Gray WA, Yeung AC, and Fitzgerald PJ
- Subjects
- Aged, Angioplasty, Balloon, Coronary adverse effects, Chi-Square Distribution, Coronary Angiography, Coronary Restenosis etiology, Female, Humans, Hyperplasia, Male, Middle Aged, Multicenter Studies as Topic, Prosthesis Design, Randomized Controlled Trials as Topic, Risk Assessment, Risk Factors, Sirolimus administration & dosage, Time Factors, Treatment Outcome, Tunica Intima diagnostic imaging, Angioplasty, Balloon, Coronary instrumentation, Cardiovascular Agents administration & dosage, Coronary Restenosis diagnostic imaging, Coronary Vessels diagnostic imaging, Drug-Eluting Stents, Paclitaxel administration & dosage, Sirolimus analogs & derivatives, Ultrasonography, Interventional
- Abstract
Background: The ZoMaxx I and II trials were randomized controlled studies of the zotarolimus-eluting, phosphorylcholine-coated, TriMaxx stent for the treatment of de novo coronary lesions. The aim of this study was to compare the vessel response between zotarolimus- (ZES) and paclitaxel-eluting stents (PES) using intravascular ultrasound (IVUS)., Methods and Results: Data were obtained from the ZoMaxx I and II trials, in which a standard IVUS parameter was available in 263 cases (baseline and 9-months follow up). Neointima-free frame ratio was calculated as the number of frames without IVUS-detectable neointima divided by the total number of frames within the stent. While an increase in vessel and plaque was observed in PES from baseline to follow up, there was no significant change in ZES. At follow up, % neointimal obstruction was significantly higher (15.4 ± 8.8% vs 11.3 ± 9.7%), and minimum lumen area at follow up was significantly smaller in ZES compared to PES. However, the incidence of IVUS-defined restenosis (maximum cross-sectional narrowing >60%) was similar in the 2 groups (3.2% vs 6.7%). Neointima-free frame ratio was significantly lower in ZES. There were 5 cases of late incomplete stent apposition in PES and none in ZES., Conclusions: These IVUS results demonstrate a similar incidence of severe narrowing between these 2 DES. There was a moderate increase in neointimal hyperplasia that was associated with a greater extent of neointimal coverage in ZES compared with PES. more...
- Published
- 2010
- Full Text
- View/download PDF
5. Short- and mid-term intravascular ultrasound analysis of the new zotarolimus-eluting stent with durable polymer – results from the RESOLUTE trial –.
- Author
-
Waseda K, Ako J, Yamasaki M, Koizumi T, Ormiston J, Worthley SG, Whitbourn RJ, Walters DL, Honda Y, Meredith IT, and Fitzgerald PJ
- Subjects
- Aged, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neointima pathology, Sirolimus administration & dosage, Time Factors, Ultrasonography, Interventional, Coronary Vessels diagnostic imaging, Drug-Eluting Stents standards, Polymers therapeutic use, Sirolimus analogs & derivatives
- Abstract
Background: The Resolute stent is a newly developed system with a bio-histocompatible polymer that allows programmed drug delivery up to 180 days. The aim of this intravascular ultrasound (IVUS) analysis was to evaluate the short- (4 months) and mid-term (9 months) efficacy using the Resolute stent., Methods and Results: Data were derived from the RESOLUTE trial, a prospective, multicenter, non-randomized, single-arm study to treat de novo native coronary artery lesions. This trial included 2 cohorts with different follow-up periods, and all enrollment patients in this trial received IVUS study. Follow-up IVUS was available in 24 patients (4-month group) and 88 patients (9-month group). Neointimal obstruction (%) was defined as neointimal volume divided by stent volume. Cross-sectional narrowing (CSN, %) was defined as neointimal area divided by stent area. No significant differences in vessel, lumen and stent volume at post-procedure were observed within stented segments between the 4- and 9-month follow-up groups. Although neointimal volume and % neointimal obstruction showed no significant difference between the 2 groups (% neointimal obstruction: 2.2 ± 2.5 vs 3.7 ± 4.0%, P=0.09), maximum CSN was significantly larger in the 9-month group. There were 7 cases of late incomplete stent apposition., Conclusions: These IVUS results showed minimum growth of neointimal proliferation by the Resolute stent throughout the stented segment up to 9 months follow up. more...
- Published
- 2010
- Full Text
- View/download PDF
6. Vascular response to overlapping everolimus-eluting stents. - Comparison with paclitaxel-eluting stents -.
- Author
-
Otake H, Honda Y, Yamasaki M, Tsujino I, Shimohama T, Sakurai R, Hasegawa T, Waseda K, Ako J, and Fitzgerald PJ
- Subjects
- Aged, Diabetes Mellitus diagnostic imaging, Diabetes Mellitus therapy, Everolimus, Female, Follow-Up Studies, Humans, Hyperlipidemias diagnostic imaging, Hyperlipidemias therapy, Hypertension diagnostic imaging, Hypertension therapy, Male, Middle Aged, Retrospective Studies, Sirolimus pharmacology, Antineoplastic Agents, Phytogenic pharmacology, Drug-Eluting Stents, Immunosuppressive Agents pharmacology, Paclitaxel pharmacology, Sirolimus analogs & derivatives, Ultrasonography, Interventional
- Abstract
Background: Overlapping drug-eluting stents might be associated with an adverse vessel response because of increased drug/polymer toxicity and lesion rigidity., Methods and Results: Lesions treated with overlapping everolimus- (EES=36) or paclitaxel-eluting stents (PES=38) were analyzed for 8-9-months by 3-dimensional intravascular ultrasound. EES were associated with significantly greater neointimal suppression in the single-strut regions than PES, with a similar trend in the overlap region. PES had significant vessel expansion in all regions, whereas there were no changes with EES. Neither stent fracture nor late incomplete stent apposition (LISA) in the overlap region was observed., Conclusions: Overlapping EES appears to be effective without vessel expansion, stent fracture or LISA for up to 8-9 months. more...
- Published
- 2010
- Full Text
- View/download PDF
7. Effect of lumen narrowing within sirolimus-eluting stents on proximal and distal vessel segments.
- Author
-
Waseda K, Ako J, Kaneda H, Miyazawa A, Shimada Y, Morino Y, Honda Y, and Fitzgerald PJ
- Subjects
- Aged, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease pathology, Coronary Stenosis diagnostic imaging, Coronary Stenosis pathology, Coronary Vessels diagnostic imaging, Coronary Vessels pathology, Female, Humans, Immunosuppressive Agents administration & dosage, Male, Middle Aged, Retrospective Studies, Safety, Ultrasonography, Coronary Artery Disease therapy, Drug-Eluting Stents adverse effects, Sirolimus administration & dosage
- Abstract
Background: Flow dynamics and shear stress may influence downstream vessel segments. The aim of this study was to investigate the potential impact of lumen narrowing within sirolimus-eluting stents (SES) on vessel response at adjacent reference sites., Methods and Results: In 135 patients after SES implantation, minimal lumen area (MLA) within the stent and average lumen area at distal or proximal adjacent reference segments (5 mm) were obtained at baseline and follow up. In the smaller in-stent MLA group (MLA <3 mm(2)), lumen area decreased significantly at the distal reference compared with the larger in-stent MLA group (MLA >or=3 mm(2)), although no significant difference was seen at the proximal reference., Conclusion: In-stent lumen patency may influence vascular responses at adjacent reference segments after SES implantation. more...
- Published
- 2008
- Full Text
- View/download PDF
8. Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque.
- Author
-
Takashima H, Ozaki Y, Yasukawa T, Waseda K, Asai K, Wakita Y, Kuroda Y, Kosaka T, Kuhara Y, and Ito T
- Subjects
- Aged, Angioplasty, Balloon, Coronary, Cholesterol, LDL blood, Coronary Artery Disease pathology, Coronary Vessels diagnostic imaging, Coronary Vessels pathology, Data Interpretation, Statistical, Female, Humans, Hyperlipidemias blood, Male, Middle Aged, Retrospective Studies, Triglycerides blood, Ultrasonography, Interventional, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease drug therapy, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hyperlipidemias drug therapy, Quinolines therapeutic use
- Abstract
Background: Recent lipid-lowering trials have reported that statin therapy may retard progression or stimulate regression of human coronary plaque. In the present study volumetric intravascular ultrasound (IVUS) analyses were performed to investigate the effect of pitavastatin, a newly developed statin, on regression of human coronary plaque., Methods and Results: Eighty-two patients matched for age and gender from 870 consecutive patients undergoing IVUS guided percutaneous coronary intervention were retrospectively assigned to either lipid-lowering therapy (n=41; pitavastatin 2 mg/day) or control group (n=41; diet only). Serial volumetric IVUS analyses of a matched left main coronary arterial site were performed. A significant reduction in low-density lipoprotein-cholesterol (LDL-C) level of 33.2% (p<0.001) was observed in the pitavastatin group. Plaque volume index (PVI) was significantly reduced in the pitavastatin group (10.6+/-9.4% decrease) compared with the control group (8.1+/-14.0% increase, p<0.001). There were positive correlations between the percent change in the PVI and follow-up LDL-C level (r=0.500, p<0.001) and the percent change in LDL-C level (r=0.479, p<0.001)., Conclusion: Lipid-lowering therapy with pitavastatin induced significant coronary plaque regression, associated with a significant reduction in the LDL-C level. The percent change in the PVI showed a significant positive correlation with the percent change in LDL-C level. more...
- Published
- 2007
- Full Text
- View/download PDF
9. Impact of angiotensin II receptor blockers on the progression and regression of coronary atherosclerosis: an intravascular ultrasound study.
- Author
-
Waseda K, Ozaki Y, Takashima H, Ako J, Yasukawa T, Ismail TF, Hishida H, and Ito T
- Subjects
- Aged, Coronary Artery Disease physiopathology, Coronary Vessels physiopathology, Disease Progression, Female, Follow-Up Studies, Humans, Male, Middle Aged, Angiotensin II Type 1 Receptor Blockers administration & dosage, Coronary Artery Disease diagnostic imaging, Coronary Artery Disease drug therapy, Coronary Vessels diagnostic imaging, Ultrasonography, Interventional methods
- Abstract
Background: Although angiotensin II receptor blockers (ARB) have been found to reduce the coronary atherosclerotic plaque burden in animal models, it is unknown whether ARB have a similar effect on human coronary arteries., Methods and Results: Serial intravascular ultrasound (IVUS) studies of the left main (LM) coronary artery were performed in 64 patients at baseline and after 7-month follow-up. All patients were divided into 2 groups (ARB group: 23 patients; non-ARB group: 41 patients). Three-dimensional volumetric analysis was done throughout the LM coronary artery, and the volume index (VI; volume/length) was calculated for the vessel (VVI), lumen (LVI), and plaque (PVI). No significant difference was found between the 2 groups in baseline clinical characteristics, including age, gender, blood pressure levels, serum cholesterol levels, the presence of diabetes and smoking status. At baseline VVI, LVI and PVI were similar between the groups. In the non-ARB group, VVI, LVI, and PVI did not change between baseline and follow-up. In the ARB group, PVI significantly decreased during follow-up (9.9 +/-3.1 mm2 vs 9.1+/-2.7 mm2, p<0.01), whereas VVI and LVI were unaffected., Conclusions: This preliminary IVUS study suggests that ARB could cause regression of coronary atherosclerosis in humans. more...
- Published
- 2006
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.